Belimumab in systemic lupus erythematosus
Open Access
Abstract
Systemic lupus erythematosus (SLE) is one of the most challenging autoimmune disorders with a complex pathophysiology and diverse clinical presentation. Many drugs have been used to treat SLE with suboptimal results, especially in patients with moderate-to-severe disease. Belimumab is the first biological drug to be approved for the treatment of SLE in more than 50 years. This monoclonal antibody blocks B-cell activating factor, a cytokine important for B-cell differentiation and survival. In this review we focus on the activity of belimumab in patients with SLE and discuss the controversies of its use.Keywords
This publication has 50 references indexed in Scilit:
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsAnnals of the Rheumatic Diseases, 2012
- Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseAnnals of the Rheumatic Diseases, 2012
- Cytokine disturbances in systemic lupus erythematosusArthritis Research & Therapy, 2011
- A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosusNature Genetics, 2009
- Finding the missing heritability of complex diseasesNature, 2009
- A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosusArthritis Care & Research, 2009
- Novel evidence‐based systemic lupus erythematosus responder indexArthritis Care & Research, 2009
- Recent insights into the genetic basis of systemic lupus erythematosusGenes & Immunity, 2009
- A role for sex chromosome complement in the female bias in autoimmune diseaseJournal of Experimental Medicine, 2008
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992